Richard C. Young & Co’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$9.49M Buy
36,267
+457
+1% +$117K 0.71% 47
2026
Q2
$9.01M Buy
35,810
+1,237
+4% +$266K 0.66% 49
2026
Q1
$7.52M Buy
34,573
+1,180
+4% +$262K 0.62% 51
2025
Q4
$7.4M Buy
33,393
+6,966
+26% +$1.59M 0.66% 51
2025
Q3
$6.12M Buy
26,427
+689
+3% +$140K 0.57% 56
2025
Q2
$4.78M Buy
25,738
+605
+2% +$112K 0.47% 60
2025
Q1
$5.27M Sell
25,133
-4
-0% -$778 0.57% 59
2024
Q4
$4.47M Buy
25,137
+2,014
+9% +$370K 0.49% 61
2024
Q3
$4.57M Buy
23,123
+3,653
+19% +$682K 0.5% 56
2024
Q2
$3.34M Buy
19,470
+5,580
+40% +$924K 0.41% 55
2024
Q1
$2.53M Buy
+13,890
New +$2.39M 0.32% 58

Other funds holding ABBV

Richard C. Young & Co's ABBV Position: Q3 2026 in Review

Richard C. Young & Co increased its AbbVie (ABBV) stake by 1.3% in Q3 2026, buying an estimated $117K and bringing the position to 36,267 shares worth $9.49M. The position accounts for 0.71% of the portfolio, ranked #47.

Richard C. Young & Co first reported a position in ABBV in Q1 2024 and has held it in 11 quarters since. 3,888 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Richard C. Young & Co held 36,267 shares of AbbVie worth $9.49M as of Q3 2026.
  • Richard C. Young & Co bought 457 AbbVie shares in Q3 2026, an estimated $117K.
  • AbbVie made up 0.71% of Richard C. Young & Co's portfolio in Q3 2026, its #47 holding.
  • Richard C. Young & Co first reported a position in AbbVie in Q1 2024 and has held it in 11 quarters since.
  • 3,888 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Richard C. Young & Co's 13F filing for Q3 2026, filed 4 Nov 2026.